Regentis Biomaterials (RGNT) Total Non-Current Liabilities (2024)
Regentis Biomaterials (RGNT) reported Total Non-Current Liabilities of $6.3 million for Q4 2024.
Regentis Biomaterials (RGNT) Total Non-Current Liabilities (2024) Analysis & Trends
Regentis Biomaterials (RGNT) has 1 years of Total Non-Current Liabilities data on file, last reported at $6.3 million in Q4 2024.
- Total Non-Current Liabilities for Q4 2024 came in at $6.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $6.3 million (changed N/A YoY), and the FY2024 annual result was $6.3 million, down 86.03% from the prior year.
- Total Non-Current Liabilities was little changed at $6.3 million in Q4 2024 per RGNT's latest filing.
- Over five years, Total Non-Current Liabilities peaked at $6.3 million in Q4 2024 and troughed at $6.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 1.91 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 24.24 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 17.13 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 941.16 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 1.03 Bn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 8.65 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 3.98 Bn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 2.10 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 12.54 Bn |
| 10 | Regentis Biomaterials | 3.72 Mn | -3.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.33 Mn |